The abstract is read at the publisher; the summary is JClub's.
A TCR warehouse library from healthy donors targeting KRAS G12d and G12v neoantigens covers ~one-quarter of pancreatic ductal adenocarcinoma patients and 10% of colorectal cancer patients.
- Why it matters: Matching mKRAS/HLA allele pairs are required for effective T cell therapies, but scalable, well-characterized TCR options across patient subsets remain limited.
- What they did: The team built and characterized a library of mutant KRAS-specific TCRs, assessing avidity and cytotoxicity and profiling antigen specificity across KRAS G12d/G12v variants and HLA contexts.
- The result: The TCRs show strong avidities and cytotoxicity comparable to benchmark TCRs, including cross-recognition of KRAS G12V and wild-type epitope with lower wild-type abundance, and interchangeable recognition of KRAS G12V on HLA-C*03:03 and HLA-C*03:04.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.